Lakewood-amedex Biotherapeutics INC

Lakewood-Amedex Biotherapeutics Inc. has released an investor presentation detailing its Bisphosphocin compounds, focusing on the lead program Nu-3 for infected diabetic foot ulcers.

Lakewood-Amedex Biotherapeutics Inc. has filed a Form 8-K announcing a 1-for-10 reverse stock split to become effective on June 19, 2026, with trading on a split-adjusted basis commencing June 22, 2026.

Lakewood-Amedex Biotherapeutics Inc. announced the appointment of Dr. Joseph Tucker to its Board of Directors, effective April 24, 2026, to enhance governance and strategic capabilities.

Lakewood-Amedex Biotherapeutics reported a Q1 loss but successfully listed on Nasdaq and raised $6.8 million in net proceeds to fund operations through 2026.

Director Joseph Edward Tucker acquired 33,784 warrants to purchase common stock in Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. has issued a proxy statement detailing proposals for its upcoming Annual Meeting, including a significant increase in authorized shares, a potential reverse stock split, and an amendment to its equity incentive plan.

Lakewood-Amedex Biotherapeutics has filed an S-1/A registration statement for a direct listing on the Nasdaq Capital Market.

Lakewood-Amedex Biotherapeutics Inc. is pursuing a direct listing on the Nasdaq Capital Market and a $7.5 million Series C Preferred Stock financing to advance its antimicrobial pipeline, despite ongoing significant losses and a going concern warning.

Lakewood-Amedex Biotherapeutics seeks a Nasdaq direct listing with a concurrent $7.5m Series C preferred financing and aims to start a Phase 2a trial for lead anti-infective Nu-3.

Lindesfarne LLC has reported a beneficial ownership of 203,360 shares, representing 9.88% of the common stock of Lakewood-Amedex Biotherapeutics Inc., as of April 17, 2026.